Dermira Inc. (NASDAQ:DERM)’s share price traded up 3.6% during mid-day trading on Thursday . The company traded as high as $30.08 and last traded at $29.99, with a volume of 360,823 shares. The stock had previously closed at $28.94.

A number of equities analysts recently issued reports on the stock. Leerink Swann reissued a “buy” rating and issued a $47.00 price target (up from $46.00) on shares of Dermira in a research note on Thursday, June 2nd. Wedbush increased their price target on shares of Dermira from $42.00 to $46.00 and gave the stock an “outperform” rating in a research note on Thursday, June 2nd. Needham & Company LLC increased their price target on shares of Dermira from $42.00 to $46.00 and gave the stock a “buy” rating in a research note on Thursday, June 2nd. Finally, Zacks Investment Research raised shares of Dermira from a “sell” rating to a “hold” rating in a research note on Friday, July 8th. One investment analyst has rated the stock with a hold rating and six have given a buy rating to the stock. The company currently has an average rating of “Buy” and a consensus target price of $40.71.

The firm’s market cap is $900.24 million. The firm has a 50 day moving average price of $29.95 and a 200 day moving average price of $26.62.

Dermira (NASDAQ:DERM) last released its quarterly earnings data on Tuesday, May 10th. The biopharmaceutical company reported ($0.95) EPS for the quarter, missing the consensus estimate of ($0.94) by $0.01. On average, equities analysts expect that Dermira Inc. will post ($3.51) EPS for the current year.

In other news, insider Eugene A. Bauer sold 2,500 shares of the company’s stock in a transaction on Monday, May 2nd. The shares were sold at an average price of $25.09, for a total value of $62,725.00. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO Thomas G. Wiggans sold 11,000 shares of the company’s stock in a transaction on Wednesday, June 1st. The shares were sold at an average price of $31.57, for a total transaction of $347,270.00. The disclosure for this sale can be found here.

Several hedge funds have added to or reduced their stakes in DERM. Jennison Associates LLC increased its stake in Dermira by 8.3% in the fourth quarter. Jennison Associates LLC now owns 1,097,201 shares of the biopharmaceutical company’s stock valued at $37,974,000 after buying an additional 83,858 shares during the period. Wells Fargo & Company MN increased its stake in Dermira by 424.6% in the fourth quarter. Wells Fargo & Company MN now owns 41,036 shares of the biopharmaceutical company’s stock valued at $1,420,000 after buying an additional 33,213 shares during the period. Morgan Stanley increased its stake in Dermira by 82.2% in the fourth quarter. Morgan Stanley now owns 42,767 shares of the biopharmaceutical company’s stock valued at $1,480,000 after buying an additional 19,299 shares during the period. Finally, Jennison Associates increased its stake in Dermira by 98.7% in the third quarter. Jennison Associates now owns 1,013,343 shares of the biopharmaceutical company’s stock valued at $23,651,000 after buying an additional 503,237 shares during the period.

Dermira, Inc is a biopharmaceutical company. The Company is focused on identifying, developing and commercializing differentiated therapies for dermatologic diseases. The Company’s portfolio includes three late-stage product candidates that target unmet needs and market opportunities, such as Cimzia (certolizumab pegol), DRM04 and DRM01.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.